AR078121A1 - Compuestos de sales de amonio cuaternario y composiciones farmaceuticas - Google Patents
Compuestos de sales de amonio cuaternario y composiciones farmaceuticasInfo
- Publication number
- AR078121A1 AR078121A1 ARP100101446A ARP100101446A AR078121A1 AR 078121 A1 AR078121 A1 AR 078121A1 AR P100101446 A ARP100101446 A AR P100101446A AR P100101446 A ARP100101446 A AR P100101446A AR 078121 A1 AR078121 A1 AR 078121A1
- Authority
- AR
- Argentina
- Prior art keywords
- unsubstituted
- group
- alkyl
- amino
- substituted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
El objetivo de la presente solicitud consiste en dar a conocer un novedoso compuesto con actividad agonista del receptor adrenérgico beta2 y actividad antagonista del receptor muscarínico. Reivindicacion 1: Un compuesto de sal de amonio cuaternario representado por la formula general (1) en la cual R1 representa un átomo de hidrogeno o un grupo alquilo C1-8 no sustituido; R2 representa un enlace simple, alquileno C1-8 no sustituido o alquileno C1-8 sustituido en los átomos de carbono con 1 a 2 átomos de oxígeno, alquenileno C2-4 no sustituido, o -O-alquileno C1-4 no sustituido; X representa un enlace simple, -O-, -CONR3-, -NR3CO- o -NR3CO-CH2-O-; donde R3 representa un átomo de hidrogeno o un grupo alquilo C1-8 no sustituido; A1 representa un enlace simple, arileno C6-10 no sustituido o arileno C6-10 sustituido con 1 a 4 sustituyentes seleccionados del grupo que consiste en un átomo de halogeno, un grupo hidroxilo, ciano, nitro, carboxilo, trifluorometilo, alquilo C1-6 no sustituido, cicloalquilo C3-8 no sustituido, alcoxi C1-6 no sustituido, cicloalquiloxi C3-8 no sustituido, mercapto, alquiltio C1-6 no sustituido, cicloalquiltio C3-8 no sustituido, amino, mono(alquilo C1-6)amino no sustituido y un lo grupo di(alquil C1-6)amino no sustituido, heteroarileno no sustituido de 5 a 10 miembros o heteroarileno de 5 a 10 miembros sustituido con 1 a 4 sustituyentes seleccionados del grupo que consiste en un átomo de halogeno, un grupo hidroxilo, ciano, nitro, carboxilo, trifluorometilo, alquilo C1-6 no sustituido, cicloalquilo C3-8 no sustituido, alcoxi C1-6 no sustituido, cicloalquiloxi C3-8 no sustituido, mercapto, alquiltio C1-6 no sustituido, cicloalquiltio C3-8 no sustituido, amino, mono(alquil C1-6)amino no sustituido y di(alquil C1-6)amino no sustituido, alquileno C1-4 no sustituido o arileno C6-10 no sustituido, donde los sustituyentes del arileno C6-10 son 1 a 3 sustituyentes seleccionados del grupo que consiste en un átomo de halogeno, un grupo hidroxilo, ciano, nitro, carboxilo, trifluorometilo, alquilo C1-6 no sustituido, cicloalquilo C3-8 no sustituido, alcoxi C1-6 no sustituido, cicloalquiloxi C3-8 no sustituido, mercapto, alquiltio C1-6 no sustituido, cicloalquilo C3-8 no sustituido, amino, mono(alquil C1-6)amino no sustituido y di(alquil C1-6)amino no sustituido, alquileno C1-4 no sustituido-heteroarilo sustituido o no sustituido de 5 a 10 miembros donde los sustituyentes del heteroarileno de 5 a 10 miembros son 1 a 3 sustituyentes seleccionados del grupo que consiste en un átomo de halogeno, un grupo hidroxilo, ciano, nitro, carboxilo, trifluorometilo, alquilo C1-6 no sustituido, cicloalquilo C3-8 no sustituido, alcoxi C1-6 no sustituido, cicloalquiloxi C3-8 no sustituido, mercapto, alquiltio C1-6 no sustituido, cicloalquilo C3-8 no sustituido, amino, mono(alquil C1-6)amino no sustituido y di(alquil C1-6)amino no sustituido, o bien cicloalquileno C3-8 no sustituido o cicloalquileno C3-8 sustituido con 1 a 3 sustituyentes seleccionados del grupo que consiste en halogeno y un grupo alquilo C1-6 no sustituido; R4 representa alquileno C1-10 no sustituido; R8 y R9 representan independientemente en cada caso un átomo de halogeno, un grupo ciano, alquilo C1-6 no sustituido, nitro, -NR10R11, donde R10 y R11 representan independientemente en cada caso un átomo de hidrogeno o un grupo alquilo C1-6 no sustituido, alcoxi C1-6 no sustituido, carboxilo, alcoxicarbonilo C1-6 no sustituido, hidroxilo, trifluorometilo, mercapto o alquiltio C1-6 no sustituido; a y b representan independientemente en cada caso un numero entero de 0 a 3; Y representa un grupo representado por la formula (2), Q representa formula (3), en la cual R6 y R7 representan independientemente en cada caso un grupo alquilo C1-6 no sustituido o un grupo alquilo C1-6 sustituido con 1 a 4 sustituyentes seleccionados del grupo que consiste en un átomo de halogeno, un grupo hidroxilo y un grupo alcoxi C1-6 no sustituido, o fenoxialquilo C8-10 no sustituido o fenoxialquilo C8-10 sustituido con 1 a 4 sustituyentes seleccionados del grupo que consiste en un átomo de halogeno, un grupo hidroxilo, alquilo C1-6 no sustituido y alcoxi C1-6 no sustituido; R5 representa un grupo alquilo C1-6 no sustituido o un grupo alquilo C1-6 sustituido con 1 a 4 sustituyentes seleccionados del grupo que consiste en un átomo de halogeno, un grupo hidroxilo y alcoxi C1-6 no sustituido; o dos cualesquiera de R5, R6 y R7 se pueden unir para formar un anillo; n representa un numero entero de 0 a 2; y m representa un numero entero de 0 a 3; W- representa un ion negativo; o una sal farmacéuticamente aceptable del mismo. Reivindicacion 12: Una composicion medicinal que tiene actividad agonista del receptor adrenérgico beta2 y actividad antagonista del receptor muscarínico, que comprende un compuesto o una sal farmacéuticamente aceptable del mismo de acuerdo con cualquiera de las reivindicaciones 1 a 10 como ingrediente activo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009110760 | 2009-04-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR078121A1 true AR078121A1 (es) | 2011-10-19 |
Family
ID=43032170
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100101446A AR078121A1 (es) | 2009-04-30 | 2010-04-29 | Compuestos de sales de amonio cuaternario y composiciones farmaceuticas |
Country Status (18)
Country | Link |
---|---|
US (1) | US9072734B2 (es) |
EP (1) | EP2426121A4 (es) |
JP (1) | JP5379224B2 (es) |
KR (1) | KR20120061061A (es) |
CN (1) | CN102459231B (es) |
AR (1) | AR078121A1 (es) |
AU (1) | AU2010242646A1 (es) |
BR (1) | BRPI1014390A2 (es) |
CA (1) | CA2760630A1 (es) |
HK (1) | HK1166790A1 (es) |
IL (1) | IL216015A0 (es) |
MX (1) | MX2011011446A (es) |
MY (1) | MY155212A (es) |
NZ (1) | NZ595810A (es) |
SG (1) | SG177468A1 (es) |
TW (1) | TWI486343B (es) |
WO (1) | WO2010126025A1 (es) |
ZA (1) | ZA201108372B (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITRM20110083U1 (it) | 2010-05-13 | 2011-11-14 | De La Cruz Jose Antonio Freire | Piastra per la costruzione di carrelli per aeroplani |
EP2386555A1 (en) | 2010-05-13 | 2011-11-16 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities |
HUE027000T2 (en) * | 2011-06-10 | 2016-08-29 | Chiesi Farm Spa | Compounds with muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
EP2592078A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
LT3345904T (lt) * | 2012-12-06 | 2020-09-25 | Chiesi Farmaceutici S.P.A. | Junginiai, pasižymintys muskarininių receptorių atžvilgiu antagonistinių ir beta-2-adrenerginių receptorių atžvilgių antagonistiniu aktyvumu |
CN105142673B8 (zh) * | 2012-12-18 | 2018-02-16 | 阿尔米雷尔有限公司 | 具有β2肾上腺素能激动剂及M3毒蕈碱拮抗剂活性的新型环己基和奎宁环基氨基甲酸酯衍生物 |
TWI643853B (zh) | 2013-02-27 | 2018-12-11 | 阿爾米雷爾有限公司 | 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類 |
TWI641373B (zh) | 2013-07-25 | 2018-11-21 | 阿爾米雷爾有限公司 | 具有蕈毒鹼受體拮抗劑和β2腎上腺素受體促效劑二者之活性的2-胺基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽 |
TW201517906A (zh) | 2013-07-25 | 2015-05-16 | Almirall Sa | 含有maba化合物和皮質類固醇之組合 |
KR20160148589A (ko) * | 2014-04-25 | 2016-12-26 | 바이엘 크롭사이언스 악티엔게젤샤프트 | 루테늄 촉매반응에 의한 아닐리드로부터 비페닐아민의 제조방법 |
TW201617343A (zh) | 2014-09-26 | 2016-05-16 | 阿爾米雷爾有限公司 | 具有β2腎上腺素促效劑及M3蕈毒拮抗劑活性之新穎雙環衍生物 |
CN104557589A (zh) * | 2014-12-24 | 2015-04-29 | 天津大学 | N-(1,1’-二芳基)取代的酰胺类衍生物的制备方法 |
TW201702225A (zh) * | 2015-05-14 | 2017-01-16 | Sichuan Haisco Pharmaceutical Co Ltd | 具有β2受體激動及M受體拮抗活性的含氮雜螺環衍生物及其在醫藥上的用途 |
TW201704211A (zh) * | 2015-05-14 | 2017-02-01 | Sichuan Haisco Pharmaceutical Co Ltd | 具有β2受體激動及M受體拮抗活性的聯苯衍生物及其在醫藥上的用途 |
CA3047023C (en) | 2016-12-14 | 2022-05-31 | Beijing Showby Pharmaceutical Co., Ltd. | Class of bifunctional compounds with quaternary ammonium salt structure |
CN108854841B (zh) * | 2018-06-25 | 2020-09-29 | 长治学院 | 一种连接基含酯基的吡咯烷类手性Gemini表面活性剂及其制备方法 |
US11841822B2 (en) | 2019-04-27 | 2023-12-12 | Cambricon Technologies Corporation Limited | Fractal calculating device and method, integrated circuit and board card |
CN111217746B (zh) * | 2020-03-10 | 2021-09-24 | 佛山市隆信医药科技有限公司 | 一种盐酸丙卡特罗的制备方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3240784A (en) * | 1966-03-15 | Esters of quaternary z-hydroxy methyl piperidinium compounds | ||
TWI249515B (en) * | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
WO2004007426A1 (en) | 2002-07-17 | 2004-01-22 | Chiang Long Y | Fullerene compounds |
CN101239971B (zh) * | 2003-02-14 | 2011-07-20 | 施万制药 | 联苯衍生物 |
PE20040950A1 (es) * | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
EP1615881A2 (en) | 2003-04-01 | 2006-01-18 | Theravance, Inc. | Diarylmethyl and related compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
JP4869066B2 (ja) | 2003-04-25 | 2012-02-01 | ケイオウエス ライフ サイエンスイズ,インコーポレイテッド | 丈夫な超多孔性ヒドロゲルの形成技術 |
US7358244B2 (en) | 2003-05-28 | 2008-04-15 | Theravance, Inc. | Azabicycloalkane compounds |
PL1656370T3 (pl) * | 2003-06-03 | 2013-03-29 | Melinta Subsidiary Corp | Biarylowe związki heterocykliczne oraz sposoby ich wytwarzania i stosowania |
PE20050231A1 (es) * | 2003-06-24 | 2005-05-20 | Novartis Ag | Derivados de piperidinium y pirrolidinium como antagonistas del receptor muscarinico m3 |
TW200534855A (en) | 2004-01-13 | 2005-11-01 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
NZ570693A (en) | 2006-03-20 | 2011-02-25 | Pfizer Ltd | Amine derivatives |
GB0702413D0 (en) | 2007-02-07 | 2007-03-21 | Argenta Discovery Ltd | New chemical compounds |
PL2242759T3 (pl) | 2008-02-06 | 2013-06-28 | Astrazeneca Ab | Związki |
-
2010
- 2010-04-27 JP JP2011511402A patent/JP5379224B2/ja not_active Expired - Fee Related
- 2010-04-27 MY MYPI2011005166A patent/MY155212A/en unknown
- 2010-04-27 BR BRPI1014390A patent/BRPI1014390A2/pt not_active IP Right Cessation
- 2010-04-27 CN CN201080029330.3A patent/CN102459231B/zh not_active Expired - Fee Related
- 2010-04-27 NZ NZ595810A patent/NZ595810A/xx not_active IP Right Cessation
- 2010-04-27 MX MX2011011446A patent/MX2011011446A/es active IP Right Grant
- 2010-04-27 EP EP10769723A patent/EP2426121A4/en not_active Withdrawn
- 2010-04-27 WO PCT/JP2010/057422 patent/WO2010126025A1/ja active Application Filing
- 2010-04-27 KR KR1020117028059A patent/KR20120061061A/ko not_active Application Discontinuation
- 2010-04-27 CA CA2760630A patent/CA2760630A1/en active Pending
- 2010-04-27 US US13/266,651 patent/US9072734B2/en not_active Expired - Fee Related
- 2010-04-27 SG SG2011097920A patent/SG177468A1/en unknown
- 2010-04-27 AU AU2010242646A patent/AU2010242646A1/en not_active Abandoned
- 2010-04-29 AR ARP100101446A patent/AR078121A1/es unknown
- 2010-04-30 TW TW099113895A patent/TWI486343B/zh not_active IP Right Cessation
-
2011
- 2011-10-27 IL IL216015A patent/IL216015A0/en unknown
- 2011-11-15 ZA ZA2011/08372A patent/ZA201108372B/en unknown
-
2012
- 2012-07-27 HK HK12107408.7A patent/HK1166790A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US9072734B2 (en) | 2015-07-07 |
SG177468A1 (en) | 2012-02-28 |
US20120046467A1 (en) | 2012-02-23 |
AU2010242646A1 (en) | 2011-11-03 |
CA2760630A1 (en) | 2010-11-04 |
EP2426121A4 (en) | 2012-10-31 |
IL216015A0 (en) | 2012-01-31 |
WO2010126025A1 (ja) | 2010-11-04 |
EP2426121A1 (en) | 2012-03-07 |
CN102459231A (zh) | 2012-05-16 |
BRPI1014390A2 (pt) | 2016-04-05 |
MX2011011446A (es) | 2011-11-18 |
JP5379224B2 (ja) | 2013-12-25 |
MY155212A (en) | 2015-09-30 |
TW201103909A (en) | 2011-02-01 |
TWI486343B (zh) | 2015-06-01 |
CN102459231B (zh) | 2015-04-22 |
JPWO2010126025A1 (ja) | 2012-11-01 |
HK1166790A1 (en) | 2012-11-09 |
KR20120061061A (ko) | 2012-06-12 |
ZA201108372B (en) | 2012-07-25 |
NZ595810A (en) | 2013-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR078121A1 (es) | Compuestos de sales de amonio cuaternario y composiciones farmaceuticas | |
AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
AR063912A1 (es) | Derivados de 1,2,4 oxadiazol. composiciones farmaceuticas. | |
AR079752A1 (es) | Prodrogas de sales de amonio cuaternario | |
AR078164A1 (es) | Derivados de isoxazolidina, proceso para preparar dichos compuestos y composiciones farmaceuticas que los comprenden | |
AR086319A1 (es) | Compuestos heterociclicos fusionados como moduladores de canal ionico | |
AR084935A1 (es) | Derivados de tipo azaindazol o diazaindazol como medicamentos | |
AR059339A1 (es) | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene | |
AR074771A1 (es) | Derivados de imidazol biciclicos sustituidos como moduladores de gamma secretasa | |
ES2670878T3 (es) | Cianometilpirazol carboxamidas como inhibidores de la Janus quinasa | |
AR061584A1 (es) | Uso de 2-aminotetralinas sustituidas para la fabricacion de un medicamento para la prevencion, alivio y/o tratamiento de diversos tipos de dolor | |
AR078152A1 (es) | Compuestos heterociclicos, utiles para el tratamiento de hcv y composiciones farmaceuticas que los comprenden | |
AR053195A1 (es) | Compuestos inhibidores de dipeptidil peptidasa-iv metodos para preparar los mismos y composiciones farmaceuticas que los contienen como un agente activo | |
AR080074A1 (es) | Naftiridinas sustituidas y su uso como medicamentos | |
AR083199A1 (es) | Compuestos de n-heteroarilo con unidad de puente ciclico | |
AR086296A1 (es) | Derivados de dihidroisoxasol utiles como parasiticidas tanto en animales como en plantas | |
MX2013011551A (es) | Compuestos y derivados hetero - biciclicos n - sustituidos para combatir las pestes en animales. | |
AR085549A1 (es) | DERIVADOS TRIAZOLIL PIPERAZINA Y TRIAZOLIL PIPERIDINA SUSTITUIDOS COMO MODULADORES DE g SECRETASA | |
AR086590A1 (es) | Compuestos de ciclohexanona y herbicidas que los comprenden | |
UY30191A1 (es) | Procedimiento para evitar las precipitaciones de fluoroquinolonas en sus disoluciones por medio de compuestos de amonio cuaternario y medicamentos conteniéndolos | |
AR061185A1 (es) | Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas. | |
EA200600760A1 (ru) | Новые соединения фенилпиридилпиперазина, способ их получения и фармацевтические композиции, содержащие их | |
DK1970372T3 (da) | Salte af 9-oxoacridin-10-eddikesyre med 1-alkylamino-1-deoxy-polyoler | |
AR072226A1 (es) | Derivados triciclicos sustituidos, proceso e intermediario para su sintesis y su uso en medicamentos para el tratamiento de enfermedades mediadas por la actividad de gsk3beta. | |
AR084916A1 (es) | Derivados de pirazol y heterociclos, composiciones farmaceuticas que los contienen y uso de los mismos para prevenir y/o tratar enfermedades inflamatorias y alergicas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |